Comparison of magnetic resonance whole body diffusion weighted imaging with FS-T2WI and FDG-PET/CT for initial staging and detection of lesion in newly diagnosed lymphoma

doi:10.16150/j.1671-2870.2021.06.005

Abstract

Abstract:

Objective: To compare the application value of magnetic resonance whole body diffusion weighted ima-ging(MR WB-DWI) combined with FS-T2WI sequence and PET/CT in detection of disease lesion and staging in newly dia-gnosed lymphoma. Methods: A total of 25 patients with newly diagnosed lymphoma and without a history of treatment for lymphoma admitted to Department of Hematology in Shanghai Ruijin Hospital from May 2014 to September 2020 were retrospectively analyzed. All the patients were histologically confirmed, including 24 cases of non-Hodgkin lymphoma and 1case of Hodgkin lymphoma. MR WB-DWI with FS-T2WI and ¹⁸F-FDG PET/CT were performed and coincidence of results between the two techniques in lesion detection and disease staging were compared. The clinical criterion was taken as the gold standard (comprehensive analysis of clinical, pathological, imaging, bone marrow puncture and 6-month follow-up results, referring to Ann-Arbor staging method). Results: Results of WB-DWI with FS-T2WI in 466 node regions out of 500 areas were congruen with those of PET/CT (K=0.807, P>0.05), there were no significant difference between two techniques in detection of intranodal lesions. The two imaging techniques agreed on 444 organs out of 450 organs analyzed (K=0.857, P>0.05). The stages based on WB-DWI with FS-T2WI was concordant with those of PET/CT in 20 patients out of 25 patients (K=0.731, P>0.05). Compared with clinical stage, PET/CT underestimated disease stage in 3 cases and WB-DWI combined with FS-T2WI underestimated disease in 2 cases. Conclusions: WB-DWI combined FS-T2WI sequence have high consistency with ¹⁸F-FDG PET/CT in lesions detection and disease staging in newly diagnosed lymphoma, and could serve as a suppliment of PET/CT.

Key words: Whole body-diffusion weighted imaging, PET/CT, Lymphoma, Staging diagnosis

CLC Number:

R733.4

YUE Jingjing, SONG Qi, JIANG Xufeng, WANG Li, ZHAO Weili, YAN Fuhua. Comparison of magnetic resonance whole body diffusion weighted imaging with FS-T2WI and FDG-PET/CT for initial staging and detection of lesion in newly diagnosed lymphoma[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 540-546.

Figures/Tables 6

References 31

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Zheng R, Zeng H, Zhang S, et al. Estimates of cancer incidence and mortality in China, 2013[J]. Chin J Cancer, 2017, 36(1):66. doi: 10.1186/s40880-017-0234-3 URL
[3]	McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma[J]. Br J Haematol, 2020, 191(3):363-381. doi: 10.1111/bjh.16872 URL
[4]	Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial[J]. Lancet, 2003, 362(9383):516-522. pmid: 12932382
[5]	Pinilla I, Gómez-León N, Del Campo-Del Val L, et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma[J]. Q J Nucl Med Mol Imaging, 2011, 55(5):567-575.
[6]	Robbins E. Radiation risks from imaging studies in children with cancer[J]. Pediatr Blood Cancer, 2008, 51(4):453-457. doi: 10.1002/pbc.21599 URL
[7]	Mayerhoefer ME, Karanikas G, Kletter K, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients[J]. Clin Cancer Res, 2014, 20(11):2984-2993. doi: 10.1158/1078-0432.CCR-13-3355 pmid: 24696320
[8]	王燕, 宋琦. 磁共振全身弥散加权成像在淋巴瘤临床诊疗方面的应用价值及研究进展[J]. 诊断学理论与实践, 2019, 18(6):692-697.
[9]	王根杰, 田颖. 不同影像学方法在淋巴瘤分期诊断中的应用[J]. 中国CT和MRI杂志, 2019, 17(4):150-152.
[10]	沈俊杰, 张俊祥, 陈守康, 等. 3.0 T MRI类PET功能成像与PET/CT在淋巴瘤分期诊断中的对比研究[J]. 临床放射学杂志, 2017, 36(5):733-738.
[11]	Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27):3059-3068. pmid: 25113753
[12]	李莉, 强永乾, 任转琴, 等. 全身弥散加权成像在全身淋巴结病变中的应用价值[J]. 实用放射学杂志, 2013, 29(4):631-634.
[13]	Spijkers S, Littooij AS, Humphries PD, et al. Imaging features of extranodal involvement in paediatric Hodgkin lymphoma[J]. Pediatr Radiol, 2019, 49(2):266-276. doi: 10.1007/s00247-018-4280-z pmid: 30515533
[14]	Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol, 2007, 25(5):571-578. pmid: 17242397
[15]	Klenk C, Gawande R, Uslu L, et al. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study[J]. Lancet Oncol, 2014, 15(3):275-285. doi: 10.1016/S1470-2045(14)70021-X URL
[16]	Regacini R, Puchnick A, Shigueoka DC, et al. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies[J]. Sao Paulo Med J, 2015, 133(2):141-150. doi: 10.1590/1516-3180.2014.8312810 pmid: 25789779
[17]	Spijkers S, Littooij AS, Kwee TC, et al. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study[J]. Eur Radiol, 2021, 31(3):1494-1504. doi: 10.1007/s00330-020-07182-0 URL
[18]	Kharuzhyk S, Zhavrid E, Dziuban A, et al. Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging[J]. Eur Radiol, 2020, 30(7):3915-3923. doi: 10.1007/s00330-020-06732-w pmid: 32103366
[19]	Stéphane V, Samuel B, Vincent D, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression(DWIBS) for initial stagi-ng of malignant lymphomas[J]. Eur J Radiol, 2013, 82(11):2011-2017. doi: 10.1016/j.ejrad.2013.05.042 pmid: 23932096
[20]	Ferrari C, Minoia C, Asabella AN, et al. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma[J]. Hell J Nucl Med, 2014, 17(Suppl 1):40-49.
[21]	Tsuji K, Kishi S, Tsuchida T, et al. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT[J]. J Magn Reson Imaging, 2015, 41(6):1601-1607. doi: 10.1002/jmri.24714 URL
[22]	Tsushima Y, Takano A, Taketomi-Takahashi A, et al. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images[J]. Acad Radiol, 2007, 14(6):643-650. pmid: 17502253
[23]	Spijkers S, Nievelstein RAJ, de Keizer B, et al. Fused high b-value diffusion weighted and T2-weighted MR ima-ges in staging of pediatric Hodgkin′s lymphoma: A pilot study[J]. Eur J Radiol, 2019, 121:108737. doi: 10.1016/j.ejrad.2019.108737 URL
[24]	Baranska D, Matera K, Podgorski M, et al. Feasibility of diffusion-weighted imaging with DWIBS in staging Hodgkin lymphoma in pediatric patients: comparison with PET/CT[J]. MAGMA, 2019, 32(3):381-390.
[25]	Wang D, Huo Y, Chen S, et al. Whole-body MRI versus ¹⁸F-FDG PET/CT for pretherapeutic assessment and sta-ging of lymphoma: a meta-analysis[J]. Onco Targets Ther, 2018, 11:3597-3608. doi: 10.2147/OTT.S148189 URL
[26]	Hong GS, Chae EJ, Ryu JS, et al. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients[J]. Cancer Imaging, 2021, 21(1):5. doi: 10.1186/s40644-020-00371-6 URL
[27]	Asenbaum U, Nolz R, Karanikas G, et al. Bone marrow involvement in malignant lymphoma: evaluation of quantitative PET and MRI biomarkers[J]. Acad Radiol, 2018, 25(4):453-460. doi: S1076-6332(17)30452-X pmid: 29199055
[28]	Wu LM, Chen FY, Jiang XX, et al. ¹⁸F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis[J]. Eur J Radiol, 2012, 81(2):303-311. doi: 10.1016/j.ejrad.2010.11.020 URL
[29]	Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27):3048-3058. pmid: 25113771
[30]	Tomizawa M, Shinozaki F, Uchida Y, et al. Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion and positron emission tomography/computed tomography of upper gastrointestinal cancers[J]. Abdom Imaging, 2015, 40(8):3012-3019. doi: 10.1007/s00261-015-0545-2 pmid: 26350283
[31]	Stecco A, Buemi F, Quagliozzi M, et al. Staging of primary abdominal lymphomas: comparison of whole-body MRI with diffusion-weighted imaging and (18)F-FDG-PET/CT[J]. Gastroenterol Res Pract, 2015, 2015:104794.

WB-DWI结合FS-T2WI	PET/CT
WB-DWI结合FS-T2WI	阳性	阴性	合计
阳性	97	18	115
阴性	16	369	385
合计	113	387	500

WB-DWI结合FS-T2WI	PET/CT
WB-DWI结合FS-T2WI	阳性	阴性	合计
阳性	19	3	22
阴性	3	425	428
合计	22	428	450

WB-DWI结合 FS-T2WI分期	PET/CT分期
WB-DWI结合 FS-T2WI分期	Ⅰ	Ⅱ	Ⅲ	Ⅳ	合计
Ⅰ	4	1			5
Ⅱ		4			4
Ⅲ		1	6	1	8
Ⅳ	1		1	6	8
合计	5	6	7	7	25